… the Alzheimer's Disease Neuroimaging Initiative database to study patients with mild cognitive
impairment who converted to Alzheimer disease … We determined the predictive utility of 25 …

… in combination with a disease-modifying treatment (DMT) can be revealed. However,
such perfect test does not exist and estimating the accuracy for predicting the response of a …

… amnestic mild cognitive impairment (MCI), Alzheimer’s disease (AD) and normally aging
elderly. … At high specificity (185–90%), combinations of MR measures had superior diagnostic …

… treatment to create a new combination therapy (combination products) and use … utility of
technologies such as computational strategies and biomarkers that may accelerate combination …

… Low cerebrospinal fluid (CSF) concentrations of the amyloid-β (Aβ 1-42 ) peptide, in combination
with high total tau and phosphorylated tau, are sensitive and specific biomarkers highly …

… Training the model with AT(N) biomarker combination revealed more prognostic utility than
… that the combination of all AT(N) biomarkers had the most prognostic utility in predicting …

… The main aim of this study was to examine the relative utility of different biomarker
modalities (and combinations thereof) to predict short-term conversion from aMCI to clinical AD …

… Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion
from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer’s disease …

… disease progression are closely related to each other but their clinical utility varies across the
different disease … An important current research focus is determining the best combination …

The development of validated biomarkers for Alzheimer’s disease is essential to improve
diagnosis and accelerate the development of new therapies. This chapter provides a roadmap …